Gynecologic Oncology 46(3): 357-360, 1992.
Piver MS, Malfetano J, Baker TR, et al.
Thirty-two stage IC or stage I grade 3 patients with invasive ovarian adenocarcinoma were treated with 6 months of adjuvant cisplatin-based chemotherapy. With a median follow-up of 60.5 months, there have been three (9%) recurrences. The 5-year progression-free survival was 90.5% and the 5-year survival was 93.3%.
Rheinische Friedrich- Wilhelms- Universität Bonn